Cardiff Oncology, Inc. filed a Form 8-K on October 27, 2026, reporting the October 22, 2026 separation of Chief Medical Officer Dr. Roger Sidhu, the appointment of Dr. Leila Alland as interim Chief Medical Officer effective October 23, 2026, and an increase in authorized common shares to 300,000,000.

Key Highlights

  • CMO departure: Dr. Roger Sidhu separated from Cardiff Oncology on October 22, 2026, "in connection with a mutually agreed upon transition," according to the filing.
  • Interim CMO appointed: Dr. Leila Alland will serve as interim Chief Medical Officer under an amended and restated consulting agreement with Leila Alland Md Consultancy LLC, commencing October 23, 2026.
  • Consulting fee: Dr. Alland will be paid a monthly fee of $35,000 and will devote up to fifty percent (50%) of her professional time to the role.
  • Agreement term: The agreement remains in effect until the earlier of April 22, 2027, or the date on which all services have been completed, with possible extension by mutual agreement.
  • Authorized shares increased: A Certificate of Amendment filed with Delaware on October 22, 2026 increased the authorized number of shares of common stock to 300,000,000.
  • Dr. Alland's background: She previously served as Chief Medical Officer at PMV Pharma, Affimed, and Tarveda Therapeutics, and held leadership roles at AstraZeneca, Bristol Myers Squibb, Novartis, and Schering-Plough.

Leadership Transition and Corporate Amendment at Cardiff Oncology

According to the filing, Dr. Roger Sidhu's separation from Cardiff Oncology (NASDAQ:CRDF) as Chief Medical Officer occurred on October 22, 2026, described as "mutually agreed upon." The same day, the company filed a Certificate of Amendment with the Delaware Secretary of State, which became effective upon filing and raised the authorized common stock from its prior level to 300,000,000 shares.

On October 23, 2026, the company entered into an amended and restated consulting agreement with Leila Alland Md Consultancy LLC to install Dr. Leila Alland as interim Chief Medical Officer. The filing states she will receive $35,000 per month and commit up to 50% of her professional time. The agreement runs through April 22, 2027 at the latest, unless services are completed earlier or the term is extended by mutual agreement.

The filing details Dr. Alland's prior experience, noting she contributed to development and approvals of oncology therapies including Tagrisso, Opdivo, Tasigna, and Caelyx during tenures at AstraZeneca, Bristol Myers Squibb, Novartis, and Schering-Plough. She received her medical degree from New York University, completed hematology/oncology training at Memorial Sloan Kettering Cancer Center, and currently serves on the Board of Directors of Abeona Therapeutics, according to the filing.

What Was Disclosed

Cardiff Oncology disclosed the departure of its Chief Medical Officer, the appointment of an interim replacement under a time-limited consulting agreement at $35,000 per month, and a Delaware charter amendment increasing authorized common shares to 300,000,000.